Lundbeck Foundation wants stronger biotech businesses in Denmark, but this doesn't rule out international growth

A managing partner at Lundbeckfonden Emerge would like to see more biotech businesses growing bigger and staying in Denmark, but this doesn't mean they can't also go public in the US.

Photo: Lundbeckfonden / PR

When Danish biotech companies reach a certain size, the growth is usually supplemented by an acquisition offer from a bigger firm, often from abroad. There's nothing wrong with this model, says Christian Elling, managing partner at Lundbeckfonden Emerge, even if he would prefer to see a more of them stay in Denmark for longer, growing domestically.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs